Tumor Types & Biomarkers
Tumor Types & Biomarkers

Explore clinical guidelines on why, whom and how to test actionable biomarkers in lung, breast, ovarian and prostate cancers.
- Lung Tumor
  
  EGFR
  
  ERBB2 (HER2)
- Breast Tumor
  
  BRCA1/2
  
  ESR1
  
  HER2
  
  PIK3CA/AKT1/PTEN
- Ovarian Tumor
  
  HRD
- Prostate Tumor
  
  HRRm
  
  PTEN
Testing Solutions
Explore Precision Medicine

Explore Precision Medicine

Implement best practices in your workflow and discover how recent advances are optimizing precision medicine.

Realizing the Potential of Precision Medicine

Collaborate across the MDT to address health inequities and optimize testing pathways.
Realizing the Potential of Precision Medicine

Latest Developments in Precision Medicine

Explore recent advances in diagnostic technologies and novel biomarkers to support precision medicine in your practice.
Latest Developments in Precision Medicine
Resources

Resources

Access a range of resources you can apply in your practice.

FAQs

Find answers to frequently asked questions about precision medicine.
FAQs

Find a Testing Lab

Search our directory of major laboratories that perform diagnostic biomarker testing.
Find a Testing Lab

Glossary

Find definitions for the most commonly used terms in precision medicine.
Glossary

Resource Library

Explore our library of videos and downloadable tools to help optimize your practice and inform your patients.
Resource Library

My Favorites

Personalize your learning by creating a bespoke collection of precision medicine resources.
My Favorites
Our Team

MDT

The Ever-Expanding Potential
of Precision Medicine

Supporting oncology care teams in removing barriers to clinically actionable biomarker testing.

Explore Biomarker Testing Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) inform biomarker testing.

Access quick-reference flow charts of National Comprehensive Cancer Network^® (NCCN^®) biomarker testing recommendations by tumor type:

Lung tumor guidelines^a

Breast tumor guidelines

Ovarian tumor guidelines

Prostate tumor guidelines

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

^aThis page contains content pertaining to non-small cell lung cancer (NSCLC) only.

NCCN^®, National Comprehensive Cancer Network^®.

The Biomarkers Informing Treatment Options

Many tumors contain actionable biomarkers. Testing unlocks this critical information, helping patients receive the right treatment for their unique cancer.

Select a biomarker below to view available diagnostic prevalence as well as practical information on how to test for them:

Lung Cancer

EGFR ERBB2 (HER2)

Ovarian Cancer

HRD

Breast Cancer

BRCA1/2 ESR1 HER2 PIK3CA/AKT1/PTEN

Prostate Cancer

HRRm, including BRCA1/2 PTEN

AKT1, serine/threonine protein kinase 1; BRCA1/2, BReast CAncer susceptibility gene 1/2; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; HRD, homologous recombination deficiency; HRRm, homologous recombination repair gene mutation; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.

Browse a selection of major laboratories offering a range of biomarker testing options.

Find a Testing Lab

This information is intended as educational and is not intended as a complete list of available testing options. AstraZeneca is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and AstraZeneca shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved.

MDT Collaboration Maximizes Biomarker Testing Impact

Explore how MDT partnership can help improve testing and ensure that the promise of precision medicine is accessible to all communities.

Keep up with the pace of precision medicine

Wherever you may be in your biomarker testing journey, stay current on recent technology advances in cancer detection and emerging biomarkers to support precision medicine in your practice.

Discover latest developments